Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Norman J Kachuck"'
Autor:
Norman J. Kachuck
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 4 (2011)
Externí odkaz:
https://doaj.org/article/2757ce1c09de45a8b87b33b02c2bd62e
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 4 (2011)
Interferon beta preparations are the most widely used initial therapies prescribed for patients with relapsing–remitting multiple sclerosis. Phase III studies have demonstrated comparable efficacy on clinical measures of disease activity, variable
Externí odkaz:
https://doaj.org/article/59129e3381d94d98ac8e65d6a7a5932b
Autor:
Melissa J. Armstrong, David Gloss, Diane Donley, Maureen Beilman, Tom Getchius, Julie Cox, David Michelson, Mauricio F. Farez, Pushpa Narayanaswami, Alexander Rae-Grant, Douglas Jeffery, James Sejvar, Yolanda Holler-Managan, Erin Lee, Jorge Correale, Norman J Kachuck, Gary S. Gronseth
Publikováno v:
Neurology. 93(13)
ObjectiveTo update the 2002 American Academy of Neurology (AAN) guideline regarding immunization and multiple sclerosis (MS).MethodsThe panel performed a systematic review and classified articles using the AAN system. Recommendations were based on ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a599d8dcda668125f0916930d5e7c4
https://pubmed.ncbi.nlm.nih.gov/31462584
https://pubmed.ncbi.nlm.nih.gov/31462584
Autor:
Norman J Kachuck
Publikováno v:
Neurology: Clinical Practice. 2:122-128
Getting the facts about risk and benefit is a critical part of medical decision-making. But when doctors and patients disagree on what is reasonable risk, it takes more than a grasp of the data to establish the way forward. Our competence as physicia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162fccc297c8a71e92616a5b0f82b4bd
https://doi.org/10.1212/cpj.0b013e31825a7848
https://doi.org/10.1212/cpj.0b013e31825a7848
Autor:
Norman J. Kachuck, Jill Conway
Publikováno v:
CONTINUUM: Lifelong Learning in Neurology. 16:234-237
The practice of neurology presents a series of ethical challenges for the clinician. These rarely have simple or straightforward solutions, but require careful consideration by the neurologist. This section of , written by colleagues with particular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70383d06a8b07e85b188ae7f57721e3e
https://doi.org/10.1212/01.con.0000389947.12477.85
https://doi.org/10.1212/01.con.0000389947.12477.85
Autor:
Norman J Kachuck, Lawrence W. Myers, Robert P. Lisak, Jana Lizrova Preiningerova, John W. Rose, Corey C. Ford, Jerry S. Wolinsky, Andrew D. Goodman, Christopher Luzzio, Kenneth P. Johnson, J. W. Lindsey, Hillel Panitch, Horea Rus, A. A. Pruitt
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing—remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd9f83113216d8d5f26adf3cb5bc48fc
https://doi.org/10.1177/1352458509358088
https://doi.org/10.1177/1352458509358088
Autor:
Norman J Kachuck
Publikováno v:
Expert Opinion on Pharmacotherapy. 10:2025-2035
Background: Fampridine-SR is under submission as the first drug to be FDA approved with an indication specifically for multiple sclerosis symptoms. Compounded forms of the active agent of Fampridine-SR (4-aminopyridine) have been used in clinical pra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5024c6eda94999ced55a135af583943
https://doi.org/10.1517/14656560903075994
https://doi.org/10.1517/14656560903075994
Autor:
Norman J Kachuck
Publikováno v:
Expert Review of Neurotherapeutics. 5:605-615
The approval of natalizumab for relapsing forms of multiple sclerosis, and the subsequent voluntary suspension of its use due to an unexpected viral infection, is a cautionary tale of how much we have to learn about how to prioritize and perform the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f962f92b3fdd912222b8a922f24d0354
https://doi.org/10.1586/14737175.5.5.605
https://doi.org/10.1586/14737175.5.5.605
Autor:
Norman J Kachuck, Margaret Burnett, Krikor Manoukian, Yervand Chakryan, David Y Ko, Leslie P. Weiner, Gurtej S. Cheema, Wendy Gilmore, Brett T. Lund, Nazely Ashikian, William Stohl, Huy Q. Ta, Susan Groshen
Publikováno v:
Journal of Neuroimmunology. 155:161-171
Multiple Sclerosis (MS) is a chronic inflammatory disease of the CNS which is characterized by large mononuclear cell infiltration and significant demyelination. CXCL8 is a chemo-attractant for both neutrophils and monocytes and triggers their firm a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771e905dee7f135fa61c496f8194bd51
https://doi.org/10.1016/j.jneuroim.2004.06.008
https://doi.org/10.1016/j.jneuroim.2004.06.008
Autor:
Hillel Panitch, J. Guarnaccia, Andrew D. Goodman, Norman J Kachuck, Robert P. Lisak, Kenneth P. Johnson, Corey C. Ford, Jerry S. Wolinsky, John W. Rose, Lawrence W. Myers, A. Pruitt, Benjamin Rix Brooks
Publikováno v:
Multiple Sclerosis Journal. 6:255-266
In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone) reduced the relapse rate and slowed accumulation of disability for patients with relapsing - remitting multiple sclerosis. Of the original 251 patients randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87b287cb6092b735d09efc4bd1b1a85
https://doi.org/10.1177/135245850000600407
https://doi.org/10.1177/135245850000600407